Sakar Healthcare Q1FY27: Revenue up 38%, PAT doubles on oncology push

Mgmt Guided Margin ImprovementOrder Pipeline DisclosedInvestor Communications View source PDF

SAKAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

—1-day move

₹829.10

prior close

₹841.60

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.3+0.2+0.5———————————

Up moveDown movePending

AI summary

Sakar Healthcare reported strong Q1FY27 results. Revenue rose 38% YoY to ₹7,297 lakhs, driven by oncology product expansion. EBITDA jumped 67% to ₹2,125 lakhs with margins expanding to 29% from 24%. PAT doubled to ₹1,028 lakhs (up 120%), margin at 14%. The company executed 65 plus oncology product contracts with 50 plus discussions underway. 16 marketing authorisations received globally. Plans to reach 100 plus overseas contracts and 300 plus dossier approvals in 2 years.

Likely market impact

Strong quarterly beat with margin expansion and oncology growth momentum signals positive outlook for shareholders.